Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
measured Hugo Gene Rank description expected final
Results: HTML CSV LaTeX
Showing element 501 to 550 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
final\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0374428\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SLC4A1AP\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2876\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1, ADAPTOR PROTEIN; KIDNEY ANION EXCHANGER ADAPTOR PROTEIN; KANADAPTIN; LUNG CANCER ONCOGENE 3. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.198705\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.188434111\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0374644\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DEGS1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
978\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
SPHINGOLIPID DELTA 4 DESATURASE; MEMBRANE FATTY ACID (LIPID) DESATURASE; DIHYDROCERAMIDE DESATURASE. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.146714\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.25535668\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0374708\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ISY1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
450\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.135742\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.27604426\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0375812\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FABP4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
292\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"FATTY ACID-BINDING PROTEIN, ADIPOCYTE (AFABP) (ADIPOCYTE LIPID-BINDING PROTEIN) (ALBP) (A-FABP). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.12452\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.301808545\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0375954\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FAM50B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1337\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
DNA SEGMENT ON CHROMOSOME 6(UNIQUE) 2654 EXPRESSED SEQUENCE; DNA SEGMENT ON CHROMOSOME X (UNIQUE) 2654 EXPRESSED SEQUENCE. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.153273\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.245283905\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0376313\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LRRC4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
541\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
NAG14 PROTEIN. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.138821\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.271077863\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
0.037683\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
C21orf66\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1558\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
GC-RICH SEQUENCE DNA-BINDING FACTOR HOMOLOG. \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.156176\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
0.241285473\vspace{3pt}}}\\\cline{2-4}
&\parbox{\wcB}{\vspace{3pt}\noindent
TLR2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1559\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
TOLL-LIKE RECEPTOR 2 PRECURSOR (TOLL/INTERLEUKIN 1 RECEPTOR-LIKE PROTEIN 4). \vspace{3pt}}&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0376832\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BRF1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
257\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"TRANSCRIPTION FACTOR IIIB 90 KDA SUBUNIT (TFIIIB90) (HTFIIIB90) (B- RELATED FACTOR 1) (HBRF) (TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, RNA POLYMERASE III, SUBUNIT 2) (TAF3B2). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.121057\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.311284767\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0376993\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FLNB\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
179\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"FILAMIN B, BETA (ACTIN BINDING PROTEIN 278); BETA FILAMIN; FILAMIN 1 (ACTIN-BINDING PROTEIN-280)-LIKE; FILAMIN B, BETA (ACTIN-BINDING PROTEIN-278); FILAMIN B, BETA. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.111754\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.33734184\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0377474\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TMCC2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
792\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.144067\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.262012813\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0377549\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FAP\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2540\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
SEPRASE (EC 3.4.21.-) (FIBROBLAST ACTIVATION PROTEIN ALPHA) (INTEGRAL MEMBRANE SERINE PROTEASE) (170-KDA MELANOMA MEMBRANE-BOUND GELATINASE). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.175918\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.214616469\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.037776\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1386\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
BA271B5.1 (SIMILAR TO RIBOSOMAL PROTEIN S7). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.154523\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.244468461\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0377969\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SLC23A2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
482\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"SOLUTE CARRIER FAMILY 23, MEMBER 2 (SODIUM-DEPENDENT VITAMIN C TRANSPORTER 2) (HSVCT2) (NA(+)/L-ASCORBIC ACID TRANSPORTER 2) (YOLK SAC PERMEASE-LIKE MOLECULE 2) (NUCLEOBASE TRANSPORTER-LIKE 1 PROTEIN). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.137792\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.274304023\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0378274\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
924\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
FATTY ACID DESATURASE 1; LINOLEOYL-COA DESATURASE (DELTA-6-DESATURASE)-LIKE 1; DELTA-5 DESATURASE; DELTA-5 FATTY ACID DESATURASE. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.1468\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.257679837\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0378287\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FUT8\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
991\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"ALPHA-(1,6)-FUCOSYLTRANSFERASE (EC 2.4.1.68) (GLYCOPROTEIN 6-ALPHA-L- FUCOSYLTRANSFERASE) (GDP-FUCOSE--GLYCOPROTEIN FUCOSYLTRANSFERASE) (GDP-L-FUC:N-ACETYL-BETA-D-GLUCOSAMINIDE ALPHA1,6-FUCOSYLTRANSFERASE) (ALPHA1-6FUCT) (FUCOSYLTRANSFERASE 8). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.148317\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.255053028\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0378408\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SLC20A2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2363\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"SOLUTE CARRIER FAMILY 20 (PHOSPHATE TRANSPORTER), MEMBER 2; GLVR-2; PIT-2; GIBBON APE LEUKEMIA VIRUS RECEPTOR 2; MURINE LEUKEMIA VIRUS, AMPHOTROPIC; RECEPTOR. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.171772\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.220296672\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0378601\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
784\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.144194\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.26256363\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0378747\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PGGT1B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
926\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
GERANYLGERANYL TRANSFERASE TYPE I BETA SUBUNIT (EC 2.5.1.-) (TYPE I PROTEIN GERANYL-GERANYLTRANSFERASE BETA SUBUNIT) (GGTASE-I-BETA). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.146984\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.257679067\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0378858\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SHC3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
476\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
NEURONAL SHC. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.138116\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.274304208\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0379081\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SHC2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
475\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
PROTEIN SCK (FRAGMENT). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.138197\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.274304797\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0379775\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BCAS2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
519\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"BREAST CARCINOMA AMPLIFIED SEQUENCE 2; SPLICEOSOME ASSOCIATED PROTEIN, AMPLIFIED IN BREAST CANCER. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.139495\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.272249901\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0379885\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GATAD2A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2901\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
P66 ALPHA. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.217449\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.174700734\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0380979\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
OXR1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
557\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
OXIDATION RESISTANCE 1. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.140583\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.270999338\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0381158\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
WDR22\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1110\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.151938\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.250864168\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0382183\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RPL34\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1956\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
60S RIBOSOMAL PROTEIN L34. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.165264\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.231256051\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0382473\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PRMT8\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
175\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
PROTEIN ARGININE N-METHYLTRANSFERASE 4 (EC 2.1.1.-). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.113378\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.337343224\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0382656\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2526\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
KERATIN ASSOCIATED PROTEIN 4-14; KERATIN ASSOCIATED PROTEIN 4.14. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.178175\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.214764136\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.03829\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EXO1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1076\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"EXONUCLEASE 1 ISOFORM B; RAD2 NUCLEASE FAMILY MEMBER, HOMOLOG OF S. CEREVISIAE EXONUCLEASE 1. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.151786\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.252263055\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.038293\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RPS7\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1388\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
40S RIBOSOMAL PROTEIN S7 (S8). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.156638\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.244468137\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0383264\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
2525\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
KERATIN ASSOCIATED PROTEIN 4.9 (FRAGMENT). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.178458\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.214764258\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\multirow{3}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
0.038359\vspace{3pt}}}&&\parbox{\wcC}{\vspace{3pt}\noindent
1823\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.163741\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
0.234266311\vspace{3pt}}}\\\cline{2-4}
&\parbox{\wcB}{\vspace{3pt}\noindent
ANK2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1824\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"ANKYRIN 2 (BRAIN ANKYRIN) (ANKYRIN B) (ANKYRIN, NONERYTHROID). \vspace{3pt}}&&\\\cline{2-4}
&\parbox{\wcB}{\vspace{3pt}\noindent
ARL3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1822\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
ADP-RIBOSYLATION FACTOR-LIKE PROTEIN 3. \vspace{3pt}}&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0383868\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EXOC3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1509\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
EXOCYST COMPLEX COMPONENT SEC6. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.158229\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.24260281\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0384193\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
C8orf79\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
418\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.138512\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.277371636\vspace{3pt}}\\\cline{1-3}\cline{5-6}
\parbox{\wcA}{\vspace{3pt}\noindent
0.038432\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
WDR82\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1392\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
0.157255\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.244392865\vspace{3pt}}\\\cline{1-3}\cline{5-6}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
0.0384502\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAEA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1616\vspace{3pt}}&&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.160453\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
0.239635283\vspace{3pt}}}\\\cline{2-3}
&\parbox{\wcB}{\vspace{3pt}\noindent
RMND5A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1617\vspace{3pt}}&&&\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
0.0384625\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1273\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
KAPPA B-RAS 1. \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.155989\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
0.246571874\vspace{3pt}}}\\\cline{2-4}
&\parbox{\wcB}{\vspace{3pt}\noindent
SNAPAP\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1274\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
SNARE ASSOCIATED PROTEIN SNAPIN. \vspace{3pt}}&&\\\hline
\multirow{3}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
0.0385127\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
FAT\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
825\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
CADHERIN-RELATED TUMOR SUPPRESSOR HOMOLOG PRECURSOR (FAT PROTEIN HOMOLOG). \vspace{3pt}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.147402\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
0.261276645\vspace{3pt}}}\\\cline{2-4}
&\parbox{\wcB}{\vspace{3pt}\noindent
STARD3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
824\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
MLN 64 PROTEIN (STAR-RELATED LIPID TRANSFER PROTEIN 3) (STARD3) (START DOMAIN-CONTAINING PROTEIN 3) (CAB1 PROTEIN). \vspace{3pt}}&&\\\cline{2-4}
&\parbox{\wcB}{\vspace{3pt}\noindent
TANC1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
823\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0385424\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LATS2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
553\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"LATS, LARGE TUMOR SUPPRESSOR, HOMOLOG 2; LATS (LARGE TUMOR SUPPRESSOR, DROSOPHILA) HOMOLOG 2. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.142223\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.270999768\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0385572\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FABP7\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
282\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"FATTY ACID-BINDING PROTEIN, BRAIN (B-FABP) (BRAIN LIPID-BINDING PROTEIN) (BLBP) (MAMMARY DERIVED GROWTH INHIBITOR RELATED). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.127753\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.301810525\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0385624\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GTDC1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1119\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.153758\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.250799308\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0385664\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
C16orf70\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1578\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
UPF0183 PROTEIN. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.160098\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.240892453\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
0.0385694\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
BBS7\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
742\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
BARDET-BIEDL SYNDROME 7 PROTEIN ISOFORM A; BBS2-LIKE 1. \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.145821\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
0.264498255\vspace{3pt}}}\\\cline{2-4}
&\parbox{\wcB}{\vspace{3pt}\noindent
HSDL2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
743\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&&\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/